Patent claims

1. A pharmaceutical composition comprising about 0.5 to 5 mg of (11β,17β)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one

of formula



or salts thereof.

2. The pharmaceutical composition according to claim 1 wherein the pharmaceutical composition comprises about 1 to 4 mg of (11β,17β)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one.

3. The pharmaceutical composition according to claim 1 to 2 wherein the pharmaceutical composition comprises about 2 mg of (11β,17β)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one.

4. The pharmaceutical composition according to claim 1, 2 or 3 comprising additionally a pharmaceutically acceptable carrier.

5. The pharmaceutical composition according to claims 1 to 4 in a form of an oral dosage, wherein the dosage form is a tablet or a capsule.

6. The pharmaceutical composition according to claims 1 to 5 for the treatment and/or prophylaxis of gynaecological disease that is preferably characterized by excessive uterine bleeding, such as fibroids of the uterus (myomas, uterine leiomyoma), endometriosis or excessive menstrual bleeds.

7. The pharmaceutical composition according to claim 6 for the treatment of fibroids of the uterus (myomas, uterine leiomyoma).

8. Oral dosage form comprising about 0.5 to 5 mg of (11β,17β)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one

of formula



or salts thereof.

9. The Oral dosage form according to claim 8 comprising about 2 mg of (11β,17β)-17-Hydroxy-11-[4-o(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one

of formula



or salts thereof.

10. The oral dosage form according to claim 8 or 9 for the treatment and/or prophylaxis of gynaecological disease that is preferably characterized by excessive uterine bleeding, such as fibroids of the uterus (myomas, uterine leiomyoma), endometriosis or excessive menstrual bleeds.

11. The oral dosage form according to claim 10 for the treatment of fibroids of the uterus (myomas, uterine leiomyoma).

12. A method for obtaining a pharmaceutical composition as described in claims 1 to 7.

13. A method for obtaining an oral dosage form as described in claims 8 to 11.

Patent claims

1. A pharmaceutical composition comprising about 0.5 to 5 mg of (11β,17β)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one

of formula



or salts thereof.

2. The pharmaceutical composition according to claim 1 wherein the pharmaceutical composition comprises about 1 to 4 mg of (11β,17β)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one.

3. The pharmaceutical composition according to claim 1 to 2 wherein the pharmaceutical composition comprises about 2 mg of (11β,17β)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one.

4. The pharmaceutical composition according to claim 1, 2 or 3 comprising additionally a pharmaceutically acceptable carrier.

5. The pharmaceutical composition according to claims 1 to 4 in a form of an oral dosage, wherein the dosage form is a tablet or a capsule.

6. The pharmaceutical composition according to claims 1 to 5 for use in the treatment and/or prophylaxis of gynaecological disease that is preferably characterized by excessive uterine bleeding, such as fibroids of the uterus, endometriosis or excessive menstrual bleeds.

7. The pharmaceutical composition according to claim 6 for use in the treatment of fibroids of the uterus.

8. Oral dosage form comprising about 0.5 to 5 mg of (11β,17β)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one

of formula



or salts thereof.

9. The Oral dosage form according to claim 8 comprising about 2 mg of (11β,17β)-17-Hydroxy-11-[4-o(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one

of formula



or salts thereof.

10. The oral dosage form according to claims 8 or 9 for use in the treatment and/or prophylaxis of gynaecological disease that is preferably characterized by excessive uterine bleeding, such as fibroids of the uterus, endometriosis or excessive menstrual bleeds.

11. The oral dosage form according to claim 10 for use in the treatment of fibroids of the uterus.

12. A method for obtaining a pharmaceutical composition as described in claims 1 to 7.

13. A method for obtaining an oral dosage form as described in claims 8 to 11.